Logo-bi
Bioimpacts. 2020;10(4): 209-215. doi: 10.34172/bi.2020.27
PMID: 32983936        PMCID: PMC7502909

Original Research

Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial

Khalil Ansarin 1,2 ORCID, Ramin Tolouian 3, Mohammadreza Ardalan 4 * ORCID, Ali Taghizadieh 2,5, Mojtaba Varshochi 6, Soheil Teimouri 5, Tahere Vaezi 5, Hamed Valizadeh 2,5, Parviz Saleh 4, Saeid Safiri 7,8 ORCID, Kenneth R. Chapman 9 ORCID

Cited by CrossRef: 29


1- Sgrignani J, Cavalli A. Computational Identification of a Putative Allosteric Binding Pocket in TMPRSS2. Front Mol Biosci. 2021;8 [Crossref]
2- Mohammadi M, Khafaee Pour Khamseh A, Varpaei H. Invasive Airway "Intubation" in COVID-19 Patients; Statistics, Causes, and Recommendations: A Review Article. Anesth Pain Med. 2021;11(3) [Crossref]
3- Naveja J, Madariaga-Mazón A, Flores-Murrieta F, Granados-Montiel J, Maradiaga-Ceceña M, Alaniz V, Maldonado-Rodriguez M, García-Morales J, Senosiain-Peláez J, Martinez-Mayorga K. Union is strength: antiviral and anti-inflammatory drugs for COVID-19. Drug Discovery Today. 2021;26(1):229 [Crossref]
4- Ben-Zuk N, Dechtman I, Henn I, Weiss L, Afriat A, Krasner E, Gal Y. Potential Prophylactic Treatments for COVID-19. Viruses. 2021;13(7):1292 [Crossref]
5- Kumar S, Priya N, Nithya S, Kannan P, Jain N, Kumar D, Magesh R, Younes S, Zayed H, Doss C. A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing. 3 Biotech. 2021;11(4) [Crossref]
6- Ku K, Shin H, Kim H, Kim B, Kim S, Kim C. Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2. J Microbiol Biotechnol. 2020;30(12):1843 [Crossref]
7- Luan B, Huynh T, Cheng X, Lan G, Wang H. Targeting Proteases for Treating COVID-19. J Proteome Res. 2020;19(11):4316 [Crossref]
8- Juul S, Nielsen E, Feinberg J, Siddiqui F, Jørgensen C, Barot E, Holgersson J, Nielsen N, Bentzer P, Veroniki A, Thabane L, Bu F, Klingenberg S, Gluud C, Jakobsen J, Bonovas S. Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PLoS ONE. 2021;16(3):e0248132 [Crossref]
9- Siemieniuk R, Bartoszko J, Ge L, Zeraatkar D, Izcovich A, Kum E, Pardo-Hernandez H, Qasim A, Martinez J, Rochwerg B, Lamontagne F, Han M, Liu Q, Agarwal A, Agoritsas T, Chu D, Couban R, Cusano E, Darzi A, Devji T, Fang B, Fang C, Flottorp S, Foroutan F, Ghadimi M, Heels-Ansdell D, Honarmand K, Hou L, Hou X, Ibrahim Q, Khamis A, Lam B, Loeb M, Marcucci M, McLeod S, Motaghi S, Murthy S, Mustafa R, Neary J, Rada G, Riaz I, Sadeghirad B, Sekercioglu N, Sheng L, Sreekanta A, Switzer C, Tendal B, Thabane L, Tomlinson G, Turner T, Vandvik P, Vernooij R, Viteri-García A, Wang Y, Yao L, Ye Z, Guyatt G, Brignardello-Petersen R. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;:m2980 [Crossref]
10- Hörnich B, Großkopf A, Schlagowski S, Tenbusch M, Kleine-Weber H, Neipel F, Stahl-Hennig C, Hahn A, Gallagher T. SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation. J Virol. 2021;95(9) [Crossref]
11- Shrimp J, Kales S, Sanderson P, Simeonov A, Shen M, Hall M. An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19. ACS Pharmacol Transl Sci. 2020;3(5):997 [Crossref]
12- Perico L, Benigni A, Remuzzi G. Angiotensin-converting enzyme 2: from a vasoactive peptide to the gatekeeper of a global pandemic. 2021;30(2):252 [Crossref]
13- Welte T, Ambrose L, Sibbring G, Sheikh S, Müllerová H, Sabir I. Current evidence for COVID-19 therapies: a systematic literature review. Eur Respir Rev. 2021;30(159):200384 [Crossref]
14- Ahmadian E, Hosseiniyan Khatibi S, Razi Soofiyani S, Abediazar S, Shoja M, Ardalan M, Zununi Vahed S. Covid‐19 and kidney injury: Pathophysiology and molecular mechanisms. Rev Med Virol. 2021;31(3) [Crossref]
15- Mareev V, Orlova Y, Plisyk A, Pavlikova E, Matskeplishvili S, Akopyan Z, Seredenina E, Potapenko A, Agapov M, Asratyan D, Dyachuk L, Samokhodskaya L, Mershina Е, Sinitsyn V, Pakhomov P, Bulanova M, Fuks A, Mareev Y, Begrambekova Y, Kamalov А. Results of Open-Label non-Randomized Comparative Clinical Trial: “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT). Kardiologiia. 2020;60(11):4 [Crossref]
16- Sagawa T, Inoue K, Takano H. Use of protease inhibitors for the prevention of COVID-19. Preventive Medicine. 2020;141:106280 [Crossref]
17- Tolouian R, Mulla Z, Jamaati H, Babamahmoodi A, Marjani M, Eskandari R, Dastan F. Effect of bromhexine in hospitalized patients with COVID-19. J Investig Med. 2021;:jim-2020-001747 [Crossref]
18- Perico L, Benigni A, Casiraghi F, Ng L, Renia L, Remuzzi G. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol. 2021;17(1):46 [Crossref]
19- Mahmoud I, Jarrar Y. Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges. Mol Biol Rep. 2021;48(5):4667 [Crossref]
20- Wambier C, McCoy J, Goren A. Male balding as a major risk factor for severe COVID-19: A possible role for targeting androgens and transmembrane protease serine 2 to protect vulnerable individuals. Journal of the American Academy of Dermatology. 2020;83(6):e401 [Crossref]
21- Fratta Pasini A, Stranieri C, Cominacini L, Mozzini C. Potential Role of Antioxidant and Anti-Inflammatory Therapies to Prevent Severe SARS-Cov-2 Complications. Antioxidants. 2021;10(2):272 [Crossref]
22- Honarmand K, Penn J, Agarwal A, Siemieniuk R, Brignardello-Petersen R, Bartoszko J, Zeraatkar D, Agoritsas T, Burns K, Fernando S, Foroutan F, Ge L, Lamontagne F, Jimenez-Mora M, Murthy S, Yepes-Nuñez J, Vandvik P, Ye Z, Rochwerg B. Clinical Trials in COVID-19 Management & Prevention: A Meta-epidemiological Study examining. Journal of Clinical Epidemiology. 2021; [Crossref]
23- Wambier C, Mehta N, Goren A, Cadegiani F. COVID‐19, androgens, and androgenic alopecia. Dermatological Reviews. 2021;2(3):146 [Crossref]

BioImpacts, as a peer-reviewed international journal, publishes all types of papers on bench-to-bedside translational aspects of pharmaceutical and biomedical sciences. As a "Publish Free" and "Access Free" journal, BioImpacts follows a constructive peer-review process with free editing service to benefit the scientific community worldwide.